If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-19. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
==== Digital PCR ==== Microfluidic devices allow the quantification of cffDNA segments in maternal plasma with accuracy beyond that of real-time PCR. Point mutations, loss of heterozygosity and aneuploidy can be detected in a single PCR step. Digital PCR can differentiate between maternal blood plasma and fetal DNA in a multiplex fashion.
=== Pregnancy and breastfeeding === Risk for the fetus has not been ruled out, per being rated pregnancy category C in Australia, meaning that it may be suspected of causing harmful effects on the human fetus (but no malformations). It appears to be safe in breastfeeding.
10 October – After making contact with his parents-in-law in Gaza, Humza Yousaf calls for a humanitarian corridor to be established. 11 October – Sean Hogg, who was given a 270-hour community order after being found guilty of twice raping a 13-year-old girl when he was 17, has the conviction quashed on appeal after prosecutors admit making mistakes during the original trial. Police are investigating fresh revelations about the Bible John killings after a podcast, Bible John: Portrait of the Serial Killer, alleged a cover up by police at the time, and that the perpetrator could be John Irvine McInnes, the cousin of a senior police officer. 12 October – Lisa Cameron, MP for East Kilbride, Strathaven and Lesmahagow, crosses the floor from the SNP to the Conservatives citing "a "toxic" culture in the SNP's Westminster group". Edinburgh Sheriff Court orders the extradition of Holocaust denier Vincent Reynouard, who faces trial in France for challenging the existence of crimes against humanity. Aberdeen City Councillor Kairin van Sweeden refers herself to the Standards Commission after describing a fellow councillor who was born in Sri Lanka as a "New Scot" during a council meeting. 13 October – After sharing a video of his mother-in-law, Elizabeth El-Nakla, describing the situation in Gaza, First Minister Humza Yousaf says that Israel is "going too far" and that innocent civilians can not simply be "collateral damage".
Sources: en.wikipedia.org
=== Comparison to other staple foods === The following table shows the nutrient content of raw plantain and other major staple foods in a raw form on a dry weight basis to account for their different water contents.
== History == Frank P. Cotter developed a "simple self sealing check valve, adapted to be connected in the pipe connections without requiring special fittings and which may be readily opened for inspection or repair" 1907 (U.S. patent 865,631). Nikola Tesla invented a deceptively simple one-way valve for fluids in 1916, called a Tesla valve. It was patented in 1920 (U.S. patent 1,329,559).
== Career at Genentech == Because of the Kleiner and Perkins investment, Swanson and Boyer dissolved their partnership and created the legal entity Genentech. Kleiner and Perkins provided $100,000 on the May closing, and acquired 20,000 shares of preferred stock from Genentech. Swanson was made the president and treasurer of Genentech, and received a $2,500 per month salary, along with 25,000 shares. This marked the end of Swanson's unemployment, and the beginning of his career at Genentech. With funding secured, and the organizational structure formed, the first logical step forward was to begin experimenting with the procedure for the synthesis of insulin. Since Genentech lacked any laboratories of its own, the Boyer lab, as well as two other labs in the San Francisco area, were to be subcontracted to carry out the experiments. However, the scientists quickly realized that a step wise approach would be more practical; rather than immediately engineer a bacterium that synthesized insulin, they would engineer a bacterium that could synthesize somatostatin, a smaller hormone. Swanson resisted at first, since he believed that “If you are going to go for something, go for the real thing.” the "real thing" being insulin, in this case. He eventually agreed, albeit grudgingly. With a new research goal set up, Swanson proceeded to establish official research agreements with the institutions. He set up research agreements with the University of California and the City of Hope. Then, in early 1977, Swanson began a second round of funding, to jumpstart the somatostatin research.
== History == Yohimbe (Pausinystalia johimbe) is a tree that grows in western and central Africa; yohimbine was named as originally extracted from the bark of yohimbe in 1896 by Adolph Spiegel (but see § Aspidosperma quebracho-blanco below). Yohimbe is used in folk medicine as an aphrodisiac. In 1900, it attracted scientific interest in Germany, where an initial report claimed that yohimbe exerted a strong aphrodisiacal effect in animals and humans. Attention soon shifted from the plant to its active constituents, particularly yohimbine. In 1943 the correct constitution of yohimbine was proposed by Witkop. Fifteen years later, a team led by Eugene van Tamelen used a 23-step synthesis to become the first persons to achieve the synthesis of yohimbine.
Sources: en.wikipedia.org
== Career == D'Abo made her screen debut in the low-budget science fiction horror film Xtro (1982), playing Analise Mercier, a French au pair, who becomes a human incubator for an alien. She appeared in the film Until September (1984) and had small roles in television mini-series based on Sidney Sheldon's novels Master of the Game (1984) and If Tomorrow Comes. She also appeared in Oscar winner Taylor Hackford's film White Nights (1985) and in an uncredited role as a woman pouring champagne to Klaus Maria Brandauer at a hunting party in the Oscar winning Out of Africa (1985), directed by Oscar winner Sydney Pollack. Other credits include Arthur the King (1985). She worked on the French stage in Lyon playing Varinia in Spartacus directed by Jacques Weber in 1981, played Roxane in Cyrano de Bergerac at the Grenier de Toulouse in 1982, then worked in a 1987 French TV movie, Les Idiots (The Idiots), written by Gérard Brach, with Jean Carmet and Jean-Pierre Marielle. D'Abo had a starring role in The Living Daylights (1987) as Kara Milovy, the sweet and vulnerable Czechoslovak cellist and would-be sniper who falls for James Bond. As a tie-in with the film, she also appeared in a Bond-themed Playboy cover and multi-page pictorial in the September 1987 issue, but later said in an interview with People magazine that "I wouldn't do those pictures now... I've learned a lot since then". She featured in the music video to the 1987 single 'So the Story Goes' by British band Living in a Box.
=== 1980s and 1990s === In 1983, the company's board of directors hired C. Stephen Lynn as president. In 1984, Lynn hired attorney J. Clifford Hudson to head the legal department. Under Lynn, Sonic and its major franchisees began to encourage the development of local-advertising cooperatives, under the leadership of Keith Sutterfield as advertising manager and later as VP of marketing in which Sutterfield developed a field structure to work with the franchisees. New franchises began to expand the company into new areas and redevelop markets that had been unsuccessful in the past. These developments, combined with a major advertising campaign featuring singer and actor Frankie Avalon, led to significant growth and a new image that made Sonic a nationally recognized name. In 1986, Lynn, with a group of investors, completed a $10-million leveraged buyout and took the company private. The next year, Sonic moved its offices to leased space in downtown Oklahoma City and began to assume a higher profile in the community. In 1991, Sonic became a publicly traded company again. By 1994, the corporation had renegotiated the franchise agreements with its franchisees. During the mid-1990s, Sonic opened 100–150 new stores a year. Beginning in 1998, Sonic began a retrofit program, called "Sonic 2000", to redesign and update all 1,750 stores in its chain to what was called a "retro-future" look.
Users have reported that mephedrone causes euphoria, stimulation, an enhanced appreciation for music, an elevated mood, decreased hostility, improved mental function and mild sexual stimulation; these effects are similar to the effects of cocaine, amphetamines and MDMA, and last different lengths of time depending on the way the drug is taken. Of 70 Dutch users of mephedrone, 58 described it as an overall pleasant experience, and 12 described it as an unpleasant experience. In a survey of UK users who had previously taken cocaine, most users found it produced a better-quality and longer-lasting high and was less addictive. The users were also asked to compare the "risk", and they answered that it was equal. A study of users in Northern Ireland found they did not equate the fact that mephedrone was legal with it being safe to use. This was contrary to another study in New Zealand, where users of benzylpiperazine thought that because it was legal, it was safe.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.